Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Importance: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal genetic arrhythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emotional stress, for which current therapy with β-blockers is incompletely effective. Flecainide acetate directly suppresses sarcoplasmic reticulum calcium release-the cellular mechanism responsible for triggering ventricular arrhythmias in CPVT-but has never been assessed prospectively. Objective: To determine whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in CPVT. Design, Setting, and Participants: This investigator-initiated, multicenter, single-blind, placebo-controlled crossover clinical trial was conducted from December 19, 2011, through December 29, 2015, with a midtrial protocol change at 10 US sites. Patients with a clinical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a baseline exercise test while receiving maximally tolerated β-blocker therapy that was continued throughout the trial. Patients were then randomized to treatment A (flecainide or placebo) for 3 months, followed by exercise testing. After a 1-week washout period, patients crossed over to treatment B (placebo or flecainide) for 3 months, followed by exercise testing. Interventions: Patients received oral flecainide or placebo twice daily, with the dosage guided by trough serum levels. Main Outcomes and Measures: The primary end point of ventricular arrhythmias during exercise was compared between the flecainide and placebo arms. Exercise tests were scored on an ordinal scale of worst ventricular arrhythmia observed (0 indicates no ectopy; 1, isolated premature ventricular beats; 2, bigeminy; 3, couplets; and 4, nonsustained ventricular tachycardia). Results: Of 14 patients (7 males and 7 females; median age, 16 years [interquartile range, 15.0-22.5 years]) randomized, 13 completed the study. The median baseline exercise test score was 3.0 (range, 0-4), with no difference noted between the baseline and placebo (median, 2.5; range, 0-4) exercise scores. The median ventricular arrhythmia score during exercise was significantly reduced by flecainide (0 [range, 0-2] vs 2.5 [range, 0-4] for placebo; P < .01), with complete suppression observed in 11 of 13 patients (85%). Overall and serious adverse events did not differ between the flecainide and placebo arms. Conclusions and Relevance: In this randomized clinical trial of patients with CPVT, flecainide plus β-blocker significantly reduced ventricular ectopy during exercise compared with placebo plus β-blocker and β-blocker alone. Trial Registration: clinicaltrials.gov Identifier: NCT01117454.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Priori, S. G., Wilde, A. A., Horie, M., Cho, Y., Behr, E. R., Berul, C., Blom, N., Brugada, J., Chiang, C.-E., Huikuri, H., et al. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2013.05.014 · Cited by 1,942
Self-citationPriori, S. G., Napolitano, C., Tiso, N., Memmi, M., Vignati, G., Bloise, R., Sorrentino, V., & Danieli, G. A. (2001) · Circulation · doi:10.1161/01.cir.103.2.196 · Cited by 1,378
Self-citationLahat, H., Pras, E., Olender, T., Avidan, N., Ben-Asher, E., Man, O., Levy-Nissenbaum, E., Khoury, A., Lorber, A., Goldman, B., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/324565 · Cited by 655
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans
Watanabe, H., Chopra, N., Laver, D., Hwang, H. S., Davies, S. S., Roach, D. E., Duff, H. J., Roden, D. M., Wilde, A. A. M., & Knollmann, B. C. (2009) · Nature Medicine · doi:10.1038/nm.1942 · Cited by 608
Self-citationHayashi, M., Denjoy, I., Extramiana, F., Maltret, A., Buisson, N. R., Lupoglazoff, J.-M., Klug, D., Hayashi, M., Takatsuki, S., Villain, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.829267 · Cited by 555
Inherited Dysfunction of Sarcoplasmic Reticulum Ca 2+ Handling and Arrhythmogenesis
Priori, S. G., & Chen, S. R. W. (2011) · Circulation Research · doi:10.1161/circresaha.110.226845 · Cited by 440
Self-citationLeft Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular Tachycardia
Wilde, A. A. M., Bhuiyan, Z. A., Crotti, L., Facchini, M., De Ferrari, G. M., Paul, T., Ferrandi, C., Koolbergen, D. R., Odero, A., & Schwartz, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708006 · Cited by 432
van der Werf, C., Kannankeril, P. J., Sacher, F., Krahn, A. D., Viskin, S., Leenhardt, A., Shimizu, W., Sumitomo, N., Fish, F. A., Bhuiyan, Z. A., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.026 · Cited by 407 · cited 1×
“C atecholaminergic polymorphic ventricular tachycardia (CPVT),araregeneticarrhythmiasyndrome, ischaracterizedbypolymorphicventricular tachycardiawithphysical or emotional stress in patients with a structurally normal heart.(1) It canbeaparticularly lethal channelopathy, resulting in symptomonsetduringchildhoodandcardi…”
Self-citationDe Ferrari, G. M., Dusi, V., Spazzolini, C., Bos, J. M., Abrams, D. J., Berul, C. I., Crotti, L., Davis, A. M., Eldar, M., Kharlap, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015731 · Cited by 298
Roston, T. M., Vinocur, J. M., Maginot, K. R., Mohammed, S., Salerno, J. C., Etheridge, S. P., Cohen, M., Hamilton, R. M., Pflaumer, A., Kanter, R. J., et al. (2015) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.114.002217 · Cited by 234
Self-citationvan der Werf, C., Zwinderman, A. H., & Wilde, A. A. M. (2012) · Europace · doi:10.1093/europace/eur277 · Cited by 202
Hwang, H. S., Hasdemir, C., Laver, D., Mehra, D., Turhan, K., Faggioni, M., Yin, H., & Knollmann, B. C. (2011) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.110.959916 · Cited by 158
Self-citationDiagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Napolitano, C., & Priori, S. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2006.12.048 · Cited by 141
Self-citationLiu, N., Denegri, M., Ruan, Y., Avelino-Cruz, J. E., Perissi, A., Negri, S., Napolitano, C., Coetzee, W. A., Boyden, P. A., & Priori, S. G. (2011) · Circulation Research · doi:10.1161/circresaha.111.247338 · Cited by 126
Self-citationMohamed, U., Gollob, M. H., Gow, R. M., & Krahn, A. D. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.08.018 · Cited by 121
Leren, I. S., Saberniak, J., Majid, E., Haland, T. F., Edvardsen, T., & Haugaa, K. H. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.09.029 · Cited by 121
Pizzale, S., Gollob, M., Gow, R., & Birnie, D. H. (2008) · Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2008.01211.x · Cited by 118
Watanabe, H., van der Werf, C., Rosés‐Noguer, F., Adler, A., Sumitomo, N., Veltmann, C., Rosso, R., Bhuiyan, Z. A., Bikker, H., Kannankeril, P. J., et al. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2012.12.035 · Cited by 105 · cited 12×
“OBJECTIVE To determine whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in CPVT. DESIGN, SETTING, AND PARTICIPANTS This investigator-initiated,multicenter, single-blind, placebo-controlled crossover c…”
InfluentialSelf-citationPriori, S. G., Napolitano, C., & Tiso, N. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00326-9 · Cited by 103
Self-citationPadfield, G. J., AlAhmari, L., Lieve, K. V. V., AlAhmari, T., Roston, T. M., Wilde, A. A. M., Krahn, A. D., & Sanatani, S. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.09.027 · Cited by 68
Khoury, A., Marai, I., Suleiman, M. A., Blich, M., Lorber, A., Gepstein, L., & Boulos, M. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2013.08.011 · Cited by 59
Gold, M. R. (2010) · Yearbook of Cardiology · doi:10.1016/s0145-4145(10)79888-9 · Cited by 6
Cited by
Zeppenfeld, K., Tfelt-Hansen, J., de Riva, M., Winkel, B. G., Behr, E. R., Blom, N. A., Charron, P., Corrado, D., Dagres, N., de Chillou, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac262 · Cited by 3,140
Self-citationTowbin, J. A., McKenna, W. J., Abrams, D. J., Ackerman, M. J., Calkins, H., Darrieux, F. C. C., Daubert, J. P., de Chillou, C., DePasquale, E. C., Desai, M. Y., et al. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.05.007 · Cited by 846
Self-citationFranklin, B. A., Thompson, P. D., Al-Zaiti, S. S., Albert, C. M., Hivert, M.-F., Levine, B. D., Lobelo, F., Madan, K., Sharrief, A. Z., Eijsvogels, T. M. H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000749 · Cited by 410
Wilde, A. A. M., Semsarian, C., Márquez, M. F., Shamloo, A. S., Ackerman, M. J., Ashley, E. A., Sternick, E. B., Barajas-Martinez, H., Behr, E. R., Bezzina, C. R., et al. (2022) · Europace · doi:10.1093/europace/euac030 · Cited by 380
Self-citationMarijon, E., Narayanan, K., Smith, K., Barra, S., Basso, C., Blom, M. T., Crotti, L., D'Avila, A., Deo, R., Dumas, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00875-9 · Cited by 313
Metadata
- Authors
- Kannankeril, P. J., Moore, J. P., Cerrone, M., Priori, S. G., Kertesz, N. J., Ro, P. S., Batra, A. S., Kaufman, E. S., Fairbrother, D. L., Saarel, E. V., Etheridge, S. P., Kanter, R. J., Carboni, M. P., Dzurik, M. V., Fountain, D., Chen, H., Ely, E. W., Roden, D. M., & Knollmann, B. C.
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-07-01
- Volume
- 2
- Issue
- 7
- Pages
- 759
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W2613997626
- Cited by
- 173
- References
- 22
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.